Aurora Investment Counsel Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Aurora Investment Counsel increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,118 shares of the biopharmaceutical company’s stock after acquiring an additional 2,768 shares during the period. Aurora Investment Counsel’s holdings in Halozyme Therapeutics were worth $1,679,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HALO. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC raised its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter worth $69,000. Parkside Financial Bank & Trust grew its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. bought a new position in shares of Halozyme Therapeutics during the third quarter valued at $127,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $61.06 on Friday. The company has a market cap of $7.52 billion, a P/E ratio of 17.80, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The stock’s fifty day moving average price is $56.50 and its 200-day moving average price is $54.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

HALO has been the topic of a number of analyst reports. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.